Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 2/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19194629 | 1.00 | IDUA (0.38) | IDUASOAT1TP53CYP1A2CYP3A4 | |
| SCHEMBL13772507 | 1.00 | IDUA (0.38) | IDUASOAT1TP53CYP1A2CYP3A4 | |
| SCHEMBL25257297 | 1.00 | IDUA (0.38) | IDUASOAT1TP53CYP1A2CYP3A4 | |
| SCHEMBL30684791 | 1.00 | IDUA (0.38) | IDUASOAT1TP53CYP1A2CYP3A4 | |
| SCHEMBL16006898 | 0.98 | IDUA (0.36) | IDUASOAT1TP53CYP1A2CYP3A4 | |
| SCHEMBL13464378 | 0.91 | — | — | |
| SCHEMBL16059643 | 0.83 | — | — | |
| SCHEMBL13736453 | 0.82 | TSHR (0.55) | MEN1KMT2AALDH1A1LMNAALOX15 | |
| SCHEMBL25408049 | 0.82 | TSHR (0.55) | MEN1KMT2AALDH1A1LMNAALOX15 | |
| SCHEMBL20626797 | 0.82 | TSHR (0.55) | MEN1KMT2AALDH1A1LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262317-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | HOFFMANN-LA ROCHE INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4558174-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| WO-2024017923-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | claimed |
| US-20250262317-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | HOFFMANN-LA ROCHE INC. (US) | 2025-08-21 | — | — | US | disclosed |
| WO-2025120218-A1 | CD16A-BINDING POLYPEPTIDE | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-06-12 | — | — | WO | disclosed |
| EP-4558174-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024087332-A1 | BIFUNCTIONAL COMPOUND USED AS TARGET PROTEIN DEGRADATION AGENT AND USE THEREOF IN TARGET PROTEIN LYSOSOMAL DEGRADATION | 深圳先进技术研究院 | 2024-05-02 | — | — | WO | disclosed |
| WO-2024017923-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| CN-117263999-A | Camptothecin prodrugs and pharmaceutical compositions thereof | 天津和美奥康医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | SANTOLECAN PHARMACEUTICALS LLC | 2021-07-29 | — | — | US | disclosed |
| US-20210139549-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2021-05-13 | — | — | US | disclosed |
| WO-2020160230-A1 | CHEMICAL REPORTER PROBES, KITS, AND METHODS OF USING THE SAME | ARTRIS THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3617235-A1 | COMPOUND HAVING SUBSTANCE THAT HAS AFFINITY FOR SOLUBLE PROTEIN, CLEAVABLE MOIETY, AND REACTIVE GROUP, OR SALT THEREOF | Ajinomoto Co., Inc. (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-20170072037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | THE UNIVERSITY OF TOLEDO (US) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262317-A1 | LINKERS FOR SITE-SPECIFIC ANTIBODY CONJUGATION | DAO, RNGTT, CTDSP1 | IDUA 234/4885SOAT1 2056/4885TP53 4383/4885 |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | DDOST, UGT2B17, UGT1A7 | IDUA 1912/4885SOAT1 302/4885TP53 2361/4885 |
| US-20170072037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | CSGALNACT1, B3GAT3, LGALS3BP | IDUA 71/4885SOAT1 959/4885TP53 115/4885 |
| US-20210139549-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | FCGR3B, FCGR2A, FCGR1A | IDUA 96/4885SOAT1 3254/4885TP53 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.